EMBO-02 Study Indicates Rapid cSDH Resorption and Pain-Free Treatments with NeoCast Liquid Embolic Agent

EMBO-02 study indicates rapid cSDH resorption and pain-free treatments with NeoCast liquid embolic agent

Arsenal Medical has announced late-breaking data from the EMBO-02 clinical study evaluating NeoCast—a next-generation, shear-responsive liquid embolic agent—in the treatment of patients with chronic subdural haematoma (cSDH) via middle meningeal artery embolisation (MMAe). Research presented across multiple sessions at the Society of NeuroInterventional Surgery (SNIS) annual meeting (14–18 July, Nashville, USA) showed that all patients met prima…

Arsenal’s NeoCast Liquid Embolic Studied in EMBO-02 Trial - Endovascular Today

July 22, 2025—Arsenal Medical recently announced findings from the EMBO-02 clinical study evaluating NeoCast, the company’s next-generation, shear-responsive liquid embolic treatment in patients with chronic subdural hematoma (cSDH) using middle meningeal artery embolization (MMAe). The solvent-free, nonadhesive liquid embolic biomaterial is designed to preferentially reach distal microvasculature without inducing pain, noted the company. The la…